Lethality of GHB.
https://www.who.int/medicines/areas/quality_safety/5GHBPreReview.pdf?ua=1.
But humans ?
https://www.researchgate.net/publication/8565872_Comparison_of_acute_lethal_toxicity_of_commonly_abused_psychoactive_substances/download
https://web.cgu.edu/faculty/gabler/J.%20Psychoactive%20PDF.pdf
https://www.ema.europa.eu/documents/scientific-discussion/xyrem-epar-scientific-discussion_en.pdf
Source, not English, run through google translate , medical
'
Depending on the dose, GHB use leads to unconsciousness, nausea, vomiting, aggressive behavior, confusion, incoherent speech, ataxia, slow heartbeat, hypothermia, random clonic movements, faecal incontinence, hallucinations, memory loss, apnea, coma and respiratory depression [Chin et al 1998 ; Li et al. 1998b; Li et al. 1998a]. Loss of short-term memory and muscle weakness are associated with oral doses of about 10 mg / kg GHB [Chin et al. 1998]. An oral dose of 20-30 mg / kg promotes REM sleep [Mamelak et al. 1986; Palatini et al. 1993]. An oral dose of 65 mg / kg (5 grams) gives sedation followed by a comatose state of 1-4 or more hours within 5 minutes [Mamelak et al. 1986], after which the user / patient suddenly wakes up. The same dose can cause muscle weakness, slow heartbeat, nausea, vomiting, random clonic movements of the face and extremities and Cheyne-Stokes respiration [Chin et al. 1998; Labor 1964]. However, the respiratory center remained sensitive to elevated carbon dioxide concentrations, GHB does not produce epileptiform changes in the EEG (no epileptic cramps); GHB seems to inhibit chemically induced cramps [Laborit 1964]. In rodents and in one small human study, it was observed that GHB stimulates the release of growth hormone, but weight loss or increased muscle growth by GHB has never been demonstrated [Cameron 2001; Li et al. 1998a]. In rats, the (intraperitoneal) lethal dose giving 50% mortality due to respiratory depression (LD50) was 1.7 g / kg [Laborit 1964].'
From me, for now.